Genentech raised the wholesale price of Tarceva -- which is approved to treat lung and pancreatic cancer -- to $2,893.86 from $2,679.50 for a 30-day supply of 150 milligram tablets, according to a document filed on Tuesday by Genentech's partner, OSI Pharmaceuticals Inc. (OSIP.O) with the U.S. Securities and Exchange Commission.
» Search Healthcare-Specific Tags: Genentech - Tarceva - OSI Pharmaceuticals
» Reuters


Comments